• Albuminuria category confirmed on repeat testing predicts kidney disease progression and mortality risk in adults with sickle cell disease

  • KDIGO heat map integrating albuminuria and estimated glomerular filtration rate further improves prediction of these longitudinal outcomes

Approximately 15% of deaths in adults with sickle cell disease (SCD) are attributed to kidney failure. Although urine albumin-to-creatinine ratio (UACR) is recommended to screen for kidney damage, its utility to predict long-term complications in SCD remains unclear. We investigated whether "Kidney Disease: Improving Global Outcomes (KDIGO)" algorithms used to assess kidney disease in the general population predicted chronic kidney disease (CKD) progression and mortality in a longitudinal cohort of 379 SCD adults from two academic institutions. KIDGO criteria include UACR detected in two consecutive measurements ≥3 months apart and a heat map integrating UACR with estimated glomerular filtration rate. KDIGO-defined CKD was present in 39.8% of individuals in our SCD cohort. Over a median follow up of 3.3 years, incremental KDIGO-defined UACR category independently predicted a 2-fold greater risk of CKD progression and 1.8-fold greater risk of mortality (P≤0.05). KDIGO-defined CKD heat map strengthened the ability to predict CKD progression and mortality risk (P≤0.0087). Our data provides clinical support for the screening utility of UACR based on repeated abnormal values ≥3 months apart. The KDIGO-heat map further refines risk of long-term outcomes in adults with SCD and should be applied to guide future studies for monitoring and intervention strategies.

This content is only available as a PDF.
Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

Article PDF first page preview

First page of KDIGO-Defined Kidney Dysfunction Predicts Long-Term Outcomes in a Multi-Center Cohort of Adults with Sickle Cell Disease

Supplemental data